Home
IVA
IVA News

Latest Inventiva S.A. American Depository Shares (IVA) News on July 12, 2025

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

Insider Monkey

17 days ago

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

GlobeNewswire

a month ago

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a month ago

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

GlobeNewswire

a month ago

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Inventiva reports 2025 First Quarter Financial Information¹

GlobeNewswire

2 months ago

Inventiva reports 2025 First Quarter Financial Information¹

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

GlobeNewswire

2 months ago

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

GlobeNewswire

2 months ago

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

GlobeNewswire

2 months ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

GlobeNewswire

2 months ago

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

GlobeNewswire

2 months ago

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

GlobeNewswire

3 months ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

GlobeNewswire

3 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Zacks

3 months ago

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

MT Newswires

3 months ago

Inventiva Completes Enrollment in Phase 3 Study of Liver Treatment

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

GlobeNewswire

3 months ago

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com

3 months ago

Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

Inventiva reports its 2024 full year results and provides a business update

GlobeNewswire

4 months ago

Inventiva reports its 2024 full year results and provides a business update

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

GlobeNewswire

4 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

GlobeNewswire

5 months ago

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

GlobeNewswire

5 months ago

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

GlobeNewswire

5 months ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

GlobeNewswire

5 months ago

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

GlobeNewswire

6 months ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

GlobeNewswire

6 months ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

7 months ago

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

7 months ago

Inventiva Splits CEO, Board Chairman Roles

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

GlobeNewswire

7 months ago

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

GlobeNewswire

7 months ago

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Inventiva reports 2024 Third Quarter Financial Information¹

GlobeNewswire

8 months ago

Inventiva reports 2024 Third Quarter Financial Information¹

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

GlobeNewswire

8 months ago

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

GlobeNewswire

8 months ago

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024

The first MASH drug could open the door for others — including GLP-1s

Pharma Voice

8 months ago

The first MASH drug could open the door for others — including GLP-1s

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

GlobeNewswire

8 months ago

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

GlobeNewswire

8 months ago

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

GlobeNewswire

9 months ago

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

MT Newswires

9 months ago

Top Premarket Decliners

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

BioPharma Dive

9 months ago

Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

GlobeNewswire

9 months ago

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Inventiva secures up to $380m for MASH treatment lanifibranor

Pharmaceutical Technology

9 months ago

Inventiva secures up to $380m for MASH treatment lanifibranor

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

Benzinga

9 months ago

Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?

MT Newswires

9 months ago

Top Premarket Gainers

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

GlobeNewswire

9 months ago

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

GlobeNewswire

9 months ago

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

9 months ago

Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

GlobeNewswire

10 months ago

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

GlobeNewswire

a year ago

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

GlobeNewswire

a year ago

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

GlobeNewswire

a year ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Inventiva announces a €20.1 million issuance of royalty certificates

GlobeNewswire

a year ago

Inventiva announces a €20.1 million issuance of royalty certificates

Inventiva reports updates from MASH/NASH treatment study

Clinical Trials Arena

a year ago

Inventiva reports updates from MASH/NASH treatment study

MT Newswires

a year ago

Inventiva Looking to Raise Additional Funds to Extend Cash Runway

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

GlobeNewswire

a year ago

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

GlobeNewswire

a year ago

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

GlobeNewswire

a year ago

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024

Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)

Zacks

a year ago

Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

GlobeNewswire

a year ago

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

GlobeNewswire

a year ago

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

GlobeNewswire

a year ago

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

GlobeNewswire

a year ago

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

GlobeNewswire

a year ago

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

Why Is Inventiva's Stock Trading Higher on Monday?

Benzinga

a year ago

Why Is Inventiva's Stock Trading Higher on Monday?

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

GlobeNewswire

a year ago

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

GlobeNewswire

a year ago

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript

Inventiva announces the nomination of Andre Turenne as Director

GlobeNewswire

a year ago

Inventiva announces the nomination of Andre Turenne as Director

Inventiva reports its 2023 full-year results

GlobeNewswire

a year ago

Inventiva reports its 2023 full-year results

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

GlobeNewswire

a year ago

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

GlobeNewswire

a year ago

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

GlobeNewswire

a year ago

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

GlobeNewswire

a year ago

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

GlobeNewswire

a year ago

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

BJ’s Restaurants, Dell, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

BJ’s Restaurants, Dell, and More Stocks See Action From Activist Investors

15 Highest Quality Multivitamin Brands of 2024

Insider Monkey

a year ago

15 Highest Quality Multivitamin Brands of 2024

Northrim BanCorp Inc (NRIM) Reports Decline in Q4 Earnings Amidst Market Challenges

GuruFocus.com

a year ago

Northrim BanCorp Inc (NRIM) Reports Decline in Q4 Earnings Amidst Market Challenges

Cardlytics Inc COO Amit Gupta Sells 72,658 Shares

GuruFocus.com

a year ago

Cardlytics Inc COO Amit Gupta Sells 72,658 Shares

XAI Octagon Floating Rate & Alternative Income Term Trust Announces Shareholder Approval of Important Proposals

Business Wire

a year ago

XAI Octagon Floating Rate & Alternative Income Term Trust Announces Shareholder Approval of Important Proposals

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

GlobeNewswire

a year ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

F&M Bank Announces Leadership Changes and Retirements of Rex Rice, EVP & Chief Lending Officer and Benét Rupp, EVP & Chief Administrative Officer

GlobeNewswire

a year ago

F&M Bank Announces Leadership Changes and Retirements of Rex Rice, EVP & Chief Lending Officer and Benét Rupp, EVP & Chief Administrative Officer

Nestlé Joins Growing List of National and Multinational Companies Operating at the Tejon Ranch Commerce Center

GlobeNewswire

a year ago

Nestlé Joins Growing List of National and Multinational Companies Operating at the Tejon Ranch Commerce Center

Associated Press Finance

a year ago

Capital Bancorp: Q4 Earnings Snapshot

Capital Bancorp, Inc. Reports Fourth Quarter 2023 Net Income of $9.0 million, or $0.65 per share

GlobeNewswire

a year ago

Capital Bancorp, Inc. Reports Fourth Quarter 2023 Net Income of $9.0 million, or $0.65 per share

Sierra Bancorp (BSRR) Earnings Expected to Grow: Should You Buy?

Zacks

a year ago

Sierra Bancorp (BSRR) Earnings Expected to Grow: Should You Buy?

Is Lincoln Educational Services Corporation's (NASDAQ:LINC) Stock's Recent Performance A Reflection Of Its Financial Health?

Simply Wall St.

a year ago

Is Lincoln Educational Services Corporation's (NASDAQ:LINC) Stock's Recent Performance A Reflection Of Its Financial Health?

Calculating The Fair Value Of Clearfield, Inc. (NASDAQ:CLFD)

Simply Wall St.

a year ago

Calculating The Fair Value Of Clearfield, Inc. (NASDAQ:CLFD)

WhiteHorse Finance, Inc. Mourns the Passing of Director Kevin Burke

PR Newswire

a year ago

WhiteHorse Finance, Inc. Mourns the Passing of Director Kevin Burke

Smith-Midland (NASDAQ:SMID) Might Be Having Difficulty Using Its Capital Effectively

Simply Wall St.

2 years ago

Smith-Midland (NASDAQ:SMID) Might Be Having Difficulty Using Its Capital Effectively

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

GlobeNewswire

2 years ago

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

GlobeNewswire

2 years ago

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

3 Strong Buys From the Refining & Marketing MLP Industry

Zacks

2 years ago

3 Strong Buys From the Refining & Marketing MLP Industry

Lands’ End Announces New Term Loan

GlobeNewswire

2 years ago

Lands’ End Announces New Term Loan

Shipping shares outpaced S&P 500 amid 2023’s rising stock market

FreightWaves

2 years ago

Shipping shares outpaced S&P 500 amid 2023’s rising stock market

BNY Mellon Municipal Bond Closed-End Funds Declare Distributions

Business Wire

2 years ago

BNY Mellon Municipal Bond Closed-End Funds Declare Distributions

Share on Social Networks: